Fontan Liver Biomarkers Predict Survival 01/31/26
Welcome to Cardiology Today â Recorded January 31, 2026. This episode summarizes 5 key cardiology studies on topics like cardiovascular-kidney-metabolic syndrome and sinoatrial node dysfunction. Key takeaway: Fontan Liver Biomarkers Predict Survival.
Article Links:
Article 1: Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples. (JAMA cardiology)
Article 2: Non-invasive biomarkers of liver disease as prognostic indicators in patients with Fontan circulation. (Heart (British Cardiac Society))
Article 3: Sex differences in the prevalence and risk factors for aortic valve calcification in the general population. (Heart (British Cardiac Society))
Article 4: Comprehensive risk factor analysis of sick sinus syndrome: a genetic, sociodemographic, clinical and laboratory investigation using the UK Biobank data. (Heart (British Cardiac Society))
Article 5: Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF. (Circulation. Heart failure)
Full episode page: https://podcast.explainheart.com/podcast/fontan-liver-biomarkers-predict-survival-01-31-26/
đ Featured Articles
Article 1: Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples.
Journal: JAMA cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41604173
Summary: The prevalence of obesity and cardiovascular-kidney-metabolic syndrome is demonstrably increasing. This rise, coupled with expanding indications for glucagonlike peptide one receptor agonists, sodium-glucose cotransporter-two inhibitors, and nonsteroidal mineralocorticoid antagonists, underscores a significant clinical challenge. It confirms a crucial need to quantify the proportion of adults who meet eligibility criteria for these therapies, including for combination treatments. This information is critical for understanding current treatment gaps and optimizing patient care in an evolving landscape.
Article 2: Non-invasive biomarkers of liver disease as prognostic indicators in patients with Fontan circulation.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41617484
Summary: The Fontan procedure carries a burden of long-term cardiac and non-cardiac complications and contributes to early mortality. Non-invasive liver fibrosis biomarkers, specifically FibroSURE testing, represent a potential prognostic tool for these patients. This study demonstrated the utility of such biomarkers to predict transplant-free survival in adults with Fontan circulation. This offers a valuable non-invasive strategy for risk stratification and management guidance in this complex patient population.
Article 3: Sex differences in the prevalence and risk factors for aortic valve calcification in the general population.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41611525
Summary: Aortic valve calcification is a recognized precursor to aortic stenosis, influenced by inflammation and lipid infiltration. This study utilized data from 30154 individuals aged 50 to 64 years from the general population to investigate sex-specific differences in aortic valve calcification. It provides characterization of the prevalence and risk factors for aortic valve calcification, particularly highlighting sex-specific variations. Understanding these differences is crucial for targeted prevention and earlier intervention strategies in the general population.
Article 4: Comprehensive risk factor analysis of sick sinus syndrome: a genetic, sociodemographic, clinical and laboratory investigation using the UK Biobank data.
Journal: Heart (British Cardiac Society)
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41605626
Summary: K. Biobank data. Sick sinus syndrome and atrial fibrillation frequently co-exist, often initiating or perpetuating each other. This study conducted a comprehensive evaluation of genetic, sociodemographic, clinical, and laboratory factors associated with the incidence of sick sinus syndrome. Using data from over 500000 individuals, it identified specific factors predictive of sick sinus syndrome development. The investigation uniquely leveraged a polygenic risk score for atrial fibrillation, revealing its association with sick sinus syndrome risk.
Article 5: Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HF.
Journal: Circulation. Heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41608790
Summary: F. The prognostic value of liver biomarkers in heart failure with mildly reduced or preserved ejection fraction has been unclear. This study evaluated the prevalence and prognostic significance of these biomarkers in patients with heart failure with mildly reduced or preserved ejection fraction. Furthermore, it assessed the effects of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, on these liver biomarkers and on crucial clinical outcomes. The analysis from Finerenone Trial to Investigate Clinical Events in Patients with Heart Failure with Preserved Ejection Fraction demonstrated specific impacts of finerenone on liver biomarkers and clinical outcomes in this patient group.
đ Transcript
Today’s date is January 31, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples. The prevalence of obesity and cardiovascular-kidney-metabolic syndrome is demonstrably increasing. This rise, coupled with expanding indications for glucagonlike peptide one receptor agonists, sodium-glucose cotransporter-two inhibitors, and nonsteroidal mineralocorticoid antagonists, underscores a significant clinical challenge. It confirms a crucial need to quantify the proportion of adults who meet eligibility criteria for these therapies, including for combination treatments. This information is critical for understanding current treatment gaps and optimizing patient care in an evolving landscape.
Article number two. Non-invasive biomarkers of liver disease as prognostic indicators in patients with Fontan circulation. The Fontan procedure carries a burden of long-term cardiac and non-cardiac complications and contributes to early mortality. Non-invasive liver fibrosis biomarkers, specifically FibroSURE testing, represent a potential prognostic tool for these patients. This study demonstrated the utility of such biomarkers to predict transplant-free survival in adults with Fontan circulation. This offers a valuable non-invasive strategy for risk stratification and management guidance in this complex patient population.
Article number three. Sex differences in the prevalence and risk factors for aortic valve calcification in the general population. Aortic valve calcification is a recognized precursor to aortic stenosis, influenced by inflammation and lipid infiltration. This study utilized data from 30154 individuals aged 50 to 64 years from the general population to investigate sex-specific differences in aortic valve calcification. It provides characterization of the prevalence and risk factors for aortic valve calcification, particularly highlighting sex-specific variations. Understanding these differences is crucial for targeted prevention and earlier intervention strategies in the general population.
Article number four. Comprehensive risk factor analysis of sick sinus syndrome: a genetic, sociodemographic, clinical and laboratory investigation using the U. K. Biobank data. Sick sinus syndrome and atrial fibrillation frequently co-exist, often initiating or perpetuating each other. This study conducted a comprehensive evaluation of genetic, sociodemographic, clinical, and laboratory factors associated with the incidence of sick sinus syndrome. Using data from over 500000 individuals, it identified specific factors predictive of sick sinus syndrome development. The investigation uniquely leveraged a polygenic risk score for atrial fibrillation, revealing its association with sick sinus syndrome risk.
Article number five. Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-H. F. The prognostic value of liver biomarkers in heart failure with mildly reduced or preserved ejection fraction has been unclear. This study evaluated the prevalence and prognostic significance of these biomarkers in patients with heart failure with mildly reduced or preserved ejection fraction. Furthermore, it assessed the effects of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, on these liver biomarkers and on crucial clinical outcomes. The analysis from Finerenone Trial to Investigate Clinical Events in Patients with Heart Failure with Preserved Ejection Fraction demonstrated specific impacts of finerenone on liver biomarkers and clinical outcomes in this patient group.
Thank you for listening. Don’t forget to subscribe.
đ Keywords
cardiovascular-kidney-metabolic syndrome, sinoatrial node dysfunction, sodium-glucose cotransporter-two inhibitors, polygenic risk score, Fontan circulation, non-invasive biomarkers, heart failure with mildly reduced ejection fraction, transplant-free survival, nonsteroidal mineralocorticoid antagonists, sex differences, finerenone, aortic stenosis, obesity, sick sinus syndrome, risk factors, general population, atrial fibrillation, heart failure with preserved ejection fraction, liver biomarkers, FibroSURE, glucagonlike peptide one receptor agonists, aortic valve calcification, genetic risk factors, mineralocorticoid receptor antagonist, liver fibrosis.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow